Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
Estimating the mean and variance from the median, range, and the size of a sample
2005 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erythropoietin, uncertainty principle and cancer related anaemia
2002
Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)
1997
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
1999
Clinical Course of Patients With Relapsed Multiple Myeloma
2004
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.
1994
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
1998 Standout
Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial
1999 Standout
THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA
1999
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Multiple myeloma
2000 Standout
Putting tumours in context
2001 Standout
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
2012
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Immunity, Inflammation, and Cancer
2010 Standout
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
2001
Systemic amyloidosis
2015 Standout
Platelets and the immune continuum
2011 Standout
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
2002
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
Fadiga relacionada ao câncer: uma revisão
2011 Standout
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
2008
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Applications of machine learning in drug discovery and development
2019 Standout
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
The Ki-67 protein: From the known and the unknown
2000 Standout
Mechanisms of Bone Metastasis
2004 Standout
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance
2009 Standout
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
2011
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Erythropoietin for patients with malignant disease
2004
Diagnosis and Management of Acquired Pure Red Cell Aplasia
2009
Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies
2006
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
1995
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
2004
Increased serum levels of β2m‐free HLA class I heavy chain in multiple myeloma
1999
Anemia of Chronic Disease
2005 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS)
2018 Standout
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology
2002
The ITP syndrome: pathogenic and clinical diversity
2009
Metalloproteinases in Multiple Myeloma: Production of Matrix Metalloproteinase-9 (MMP-9), Activation of proMMP-2, and Induction of MMP-1 by Myeloma Cells
1997
Human Parvovirus B19
2002 Standout
Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
1995
Pure red blood cell aplasia associated with parvovirus B19 infection in large granular lymphocyte leukemia [letter]
1996
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
2014
A new staging system for multiple myeloma based on the number of S- phase plasma cells
1995
Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
1998
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Autotransplants in multiple myeloma: what have we learned?
1996
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
2006
Multiple Myeloma
2011 Standout
Use of Recombinant Human Erythropoietin Outside the Setting of Uremia
1997
Erythropoietin or darbepoetin for patients with cancer
2012
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
1999
Industry sponsorship and research outcome
2017 Standout
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
1995
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
International Staging System for Multiple Myeloma
2005 Standout
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006
Works of JA Lust being referenced
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
2013
Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma
1998
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
1994
Clinical parameters for determining when and when not to treat essential thrombocythemia.
1999
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
1995
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
1994